Target intelligence / Profile preview

Human MutS alpha mismatch repair complex (hMutSα) (hMutSα)

Target
hMutSα
Molecular classification
DNA repair protein complex, ATPase, Heterodimer
01

Overview

The Human MutS alpha (hMutSα) mismatch repair complex is a protein heterodimer consisting of MSH2 and MSH6 that serves as a primary sensor for DNA replication errors (UniProt P43246, P52701). It specifically recognizes base-base mismatches and small insertion-deletion loops, initiating the DNA mismatch repair (MMR) pathway to maintain genomic stability (Kunkel and Erie, 2005, PMID: 16038671). In a pharmacological context, hMutSα is the critical mediator of the cytotoxicity of thiopurine drugs, such as 6-thioguanine, and alkylating agents like temozolomide. These drugs result in the formation of 6-methylthioguanine (6-MeTG) or O6-methylguanine (O6-MeG) in DNA, which pair with thymine; hMutSα recognizes these mismatches and triggers a "futile repair cycle" or direct apoptotic signaling (Karran and Attard, 2008, PMID: 18311171). Deficiency in this complex, often seen in Lynch syndrome or sporadic cancers with microsatellite instability, leads to high mutation rates and profound resistance to these chemotherapeutic agents (Li, 2008, PMID: 18246114). Thus, hMutSα is both a guardian of the genome and a necessary component for the efficacy of specific DNA-damaging therapies. Its role in drug response makes it a significant factor in personalized oncology and the study of drug resistance mechanisms.

Other names
MSH2-MSH6 heterodimerMutS alphaHuman MutS homolog alphahMutS alphaDNA mismatch repair protein MSH2-MSH6 complex
02

Mechanism of action

The complex recognizes DNA lesions such as 6-methylthioguanine:thymine or O6-methylguanine:thymine mismatches, which triggers a futile repair cycle or direct signaling to the cell cycle machinery (e.g., ATR/CHK1), ultimately leading to G2/M arrest and apoptosis (PMID: 10523315, 18311171).

03

Biological functions

DNA mismatch repairDNA damage recognitionApoptosis inductionGenome stability maintenance
04

Disease associations

Lynch syndromeColorectal cancerEndometrial cancerThiopurine resistance
05

Safety considerations

Loss of function leads to hypermutationResistance to thiopurine and alkylating agentsIncreased risk of secondary malignancies (Lynch syndrome)
06

Interacting drugs

6-Thioguanine

3 more in the full profile.

07

Biomarkers

Microsatellite instability (MSI)MSH2 protein expression (IHC)MSH6 protein expression (IHC)Germline MSH2/MSH6 mutations

Beyond the preview

Go deeper on Human MutS alpha mismatch repair complex (hMutSα) (hMutSα).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human MutS alpha mismatch repair complex (hMutSα) (hMutSα).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call